Global Human Rotavirus Vaccine

Human Rotavirus Vaccine Comprehensive Study by Type (Rotarix, Rotavac, Rotavin-M1, Lanzhou Lamb, Others), Application (Hospitals, Clinics, Academic and Research, Others), Distribution Channel (Hospital Pharmacies, Drug Stores) Players and Region - Global Market Outlook to 2030

Human Rotavirus Vaccine Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Human Rotavirus Vaccine Market Overview:
It is estimated that about 600,000 children die every year from rotavirus, with more than 80% of all rotavirus-related deaths occurring in resource-poor countries in south Asia and sub-Saharan Africa. Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children around the globe and continues to have a major global impact on childhood morbidity and mortality. The human rotavirus vaccine is considered highly effective in preventing severe gastrointestinal disease. The human rotavirus vaccine is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus disease. As per latest study released by AMA Research, the Global Human Rotavirus Vaccine market is expected to see growth rate of 6.2%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increased Research and Development Investment and Rise in the Government Initiatives

Market Growth Drivers:
Increased Prevalence of Rotavirus Infection, Increased Number of Hospitals and Diagnostic Centres and Rise in Healthcare Infrastructure among Developing Countries

Challenges:
Stringent Government Rules and Regulations

Restraints:
Immune Reactions and Side Effects of Vaccine

Opportunities:
Growing Healthcare Industry Worldwide and Increasing Demand from End-users

Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Merck & Co., Inc. (United States), Bharat Biotech International Limited (India), GlaxoSmithKline plc. (United Kingdom), Sanofi S.A. (France), Lanzhou Institute of Biologicals Products Co., Ltd (China), BIOVIRx Inc (United States), Serum Institute of India Pvt. Ltd. (India), Biological E (India) and Bio Farma (Indonesia). Analyst at AMA Research see Global Players to retain maximum share of Global Human Rotavirus Vaccine market by 2030. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Human Rotavirus Vaccine market.

Latest Market Insights:
In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of clinical trial Phase 3 efficacy study of rotavirus vaccine BRV-PV, ROTASIIL. The study has showed that vaccine is safe, well tolerated, and to provide significant efficacy against severe rotavirus gastroenteritis.

In December 2020, Bharat Biotech International launched a new variant of its rotavirus vaccine, Rotavac 5D. This variant is unique as it can be administered without a buffer and has a low dose volume, facilitating easier vaccine logistics, cold chain management, and lower biomedical waste disposal post-vaccination.

What Can be Explored with the Human Rotavirus Vaccine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Human Rotavirus Vaccine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Human Rotavirus Vaccine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Human Rotavirus Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Human Rotavirus Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Human Rotavirus Vaccine Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Rotarix
  • Rotavac
  • Rotavin-M1
  • Lanzhou Lamb
  • Others
By Application
  • Hospitals
  • Clinics
  • Academic and Research
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Rotavirus Infection
      • 3.2.2. Increased Number of Hospitals and Diagnostic Centres
      • 3.2.3. Rise in Healthcare Infrastructure among Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Investment
      • 3.4.2. Rise in the Government Initiatives
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Rotavirus Vaccine, by Type, Application, Distribution Channel and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Rotavirus Vaccine (Value)
      • 5.2.1. Global Human Rotavirus Vaccine by: Type (Value)
        • 5.2.1.1. Rotarix
        • 5.2.1.2. Rotavac
        • 5.2.1.3. Rotavin-M1
        • 5.2.1.4. Lanzhou Lamb
        • 5.2.1.5. Others
      • 5.2.2. Global Human Rotavirus Vaccine by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Academic and Research
        • 5.2.2.4. Others
      • 5.2.3. Global Human Rotavirus Vaccine by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Drug Stores
      • 5.2.4. Global Human Rotavirus Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Human Rotavirus Vaccine (Volume)
      • 5.3.1. Global Human Rotavirus Vaccine by: Type (Volume)
        • 5.3.1.1. Rotarix
        • 5.3.1.2. Rotavac
        • 5.3.1.3. Rotavin-M1
        • 5.3.1.4. Lanzhou Lamb
        • 5.3.1.5. Others
      • 5.3.2. Global Human Rotavirus Vaccine by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Academic and Research
        • 5.3.2.4. Others
      • 5.3.3. Global Human Rotavirus Vaccine by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Drug Stores
      • 5.3.4. Global Human Rotavirus Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Human Rotavirus Vaccine (Price)
      • 5.4.1. Global Human Rotavirus Vaccine by: Type (Price)
  • 6. Human Rotavirus Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bharat Biotech International Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi S.A. (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lanzhou Institute of Biologicals Products Co., Ltd (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BIOVIRx Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Serum Institute of India Pvt. Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biological E (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio Farma (Indonesia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Human Rotavirus Vaccine Sale, by Type, Application, Distribution Channel and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Rotavirus Vaccine (Value)
      • 7.2.1. Global Human Rotavirus Vaccine by: Type (Value)
        • 7.2.1.1. Rotarix
        • 7.2.1.2. Rotavac
        • 7.2.1.3. Rotavin-M1
        • 7.2.1.4. Lanzhou Lamb
        • 7.2.1.5. Others
      • 7.2.2. Global Human Rotavirus Vaccine by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Academic and Research
        • 7.2.2.4. Others
      • 7.2.3. Global Human Rotavirus Vaccine by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Drug Stores
      • 7.2.4. Global Human Rotavirus Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Human Rotavirus Vaccine (Volume)
      • 7.3.1. Global Human Rotavirus Vaccine by: Type (Volume)
        • 7.3.1.1. Rotarix
        • 7.3.1.2. Rotavac
        • 7.3.1.3. Rotavin-M1
        • 7.3.1.4. Lanzhou Lamb
        • 7.3.1.5. Others
      • 7.3.2. Global Human Rotavirus Vaccine by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Academic and Research
        • 7.3.2.4. Others
      • 7.3.3. Global Human Rotavirus Vaccine by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Drug Stores
      • 7.3.4. Global Human Rotavirus Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Human Rotavirus Vaccine (Price)
      • 7.4.1. Global Human Rotavirus Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Rotavirus Vaccine: by Type(USD Million)
  • Table 2. Human Rotavirus Vaccine Rotarix , by Region USD Million (2018-2023)
  • Table 3. Human Rotavirus Vaccine Rotavac , by Region USD Million (2018-2023)
  • Table 4. Human Rotavirus Vaccine Rotavin-M1 , by Region USD Million (2018-2023)
  • Table 5. Human Rotavirus Vaccine Lanzhou Lamb , by Region USD Million (2018-2023)
  • Table 6. Human Rotavirus Vaccine Others , by Region USD Million (2018-2023)
  • Table 7. Human Rotavirus Vaccine: by Application(USD Million)
  • Table 8. Human Rotavirus Vaccine Hospitals , by Region USD Million (2018-2023)
  • Table 9. Human Rotavirus Vaccine Clinics , by Region USD Million (2018-2023)
  • Table 10. Human Rotavirus Vaccine Academic and Research , by Region USD Million (2018-2023)
  • Table 11. Human Rotavirus Vaccine Others , by Region USD Million (2018-2023)
  • Table 12. Human Rotavirus Vaccine: by Distribution Channel(USD Million)
  • Table 13. Human Rotavirus Vaccine Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Human Rotavirus Vaccine Drug Stores , by Region USD Million (2018-2023)
  • Table 15. South America Human Rotavirus Vaccine, by Country USD Million (2018-2023)
  • Table 16. South America Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 17. South America Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 18. South America Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 19. Brazil Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 20. Brazil Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 21. Brazil Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 22. Argentina Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 23. Argentina Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 24. Argentina Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 25. Rest of South America Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 27. Rest of South America Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 28. Asia Pacific Human Rotavirus Vaccine, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 31. Asia Pacific Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 32. China Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 33. China Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 34. China Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 35. Japan Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 36. Japan Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 37. Japan Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 38. India Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 39. India Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 40. India Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 41. South Korea Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 42. South Korea Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 43. South Korea Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 44. Taiwan Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 45. Taiwan Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 46. Taiwan Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 47. Australia Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 48. Australia Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 49. Australia Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 53. Europe Human Rotavirus Vaccine, by Country USD Million (2018-2023)
  • Table 54. Europe Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 55. Europe Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 56. Europe Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 57. Germany Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 58. Germany Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 59. Germany Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 60. France Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 61. France Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 62. France Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 63. Italy Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 64. Italy Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 65. Italy Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 66. United Kingdom Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 67. United Kingdom Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 68. United Kingdom Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 69. Netherlands Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 70. Netherlands Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 71. Netherlands Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 72. Rest of Europe Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 74. Rest of Europe Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 75. MEA Human Rotavirus Vaccine, by Country USD Million (2018-2023)
  • Table 76. MEA Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 77. MEA Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 78. MEA Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 79. Middle East Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 80. Middle East Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 81. Middle East Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 82. Africa Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 83. Africa Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 84. Africa Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 85. North America Human Rotavirus Vaccine, by Country USD Million (2018-2023)
  • Table 86. North America Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 87. North America Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 88. North America Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 89. United States Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 90. United States Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 91. United States Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 92. Canada Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 93. Canada Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 94. Canada Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 95. Mexico Human Rotavirus Vaccine, by Type USD Million (2018-2023)
  • Table 96. Mexico Human Rotavirus Vaccine, by Application USD Million (2018-2023)
  • Table 97. Mexico Human Rotavirus Vaccine, by Distribution Channel USD Million (2018-2023)
  • Table 98. Human Rotavirus Vaccine Sales: by Type(K Units)
  • Table 99. Human Rotavirus Vaccine Sales Rotarix , by Region K Units (2018-2023)
  • Table 100. Human Rotavirus Vaccine Sales Rotavac , by Region K Units (2018-2023)
  • Table 101. Human Rotavirus Vaccine Sales Rotavin-M1 , by Region K Units (2018-2023)
  • Table 102. Human Rotavirus Vaccine Sales Lanzhou Lamb , by Region K Units (2018-2023)
  • Table 103. Human Rotavirus Vaccine Sales Others , by Region K Units (2018-2023)
  • Table 104. Human Rotavirus Vaccine Sales: by Application(K Units)
  • Table 105. Human Rotavirus Vaccine Sales Hospitals , by Region K Units (2018-2023)
  • Table 106. Human Rotavirus Vaccine Sales Clinics , by Region K Units (2018-2023)
  • Table 107. Human Rotavirus Vaccine Sales Academic and Research , by Region K Units (2018-2023)
  • Table 108. Human Rotavirus Vaccine Sales Others , by Region K Units (2018-2023)
  • Table 109. Human Rotavirus Vaccine Sales: by Distribution Channel(K Units)
  • Table 110. Human Rotavirus Vaccine Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 111. Human Rotavirus Vaccine Sales Drug Stores , by Region K Units (2018-2023)
  • Table 112. South America Human Rotavirus Vaccine Sales, by Country K Units (2018-2023)
  • Table 113. South America Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 114. South America Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 115. South America Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 116. Brazil Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 117. Brazil Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 118. Brazil Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 119. Argentina Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 120. Argentina Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 121. Argentina Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 122. Rest of South America Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 123. Rest of South America Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 124. Rest of South America Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 125. Asia Pacific Human Rotavirus Vaccine Sales, by Country K Units (2018-2023)
  • Table 126. Asia Pacific Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 127. Asia Pacific Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 128. Asia Pacific Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 129. China Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 130. China Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 131. China Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 132. Japan Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 133. Japan Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 134. Japan Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 135. India Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 136. India Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 137. India Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 138. South Korea Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 139. South Korea Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 140. South Korea Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 141. Taiwan Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 142. Taiwan Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 143. Taiwan Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 144. Australia Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 145. Australia Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 146. Australia Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 147. Rest of Asia-Pacific Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 148. Rest of Asia-Pacific Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 149. Rest of Asia-Pacific Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 150. Europe Human Rotavirus Vaccine Sales, by Country K Units (2018-2023)
  • Table 151. Europe Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 152. Europe Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 153. Europe Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 154. Germany Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 155. Germany Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 156. Germany Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 157. France Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 158. France Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 159. France Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 160. Italy Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 161. Italy Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 162. Italy Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 163. United Kingdom Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 164. United Kingdom Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 165. United Kingdom Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 166. Netherlands Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 167. Netherlands Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 168. Netherlands Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 169. Rest of Europe Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 170. Rest of Europe Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 171. Rest of Europe Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 172. MEA Human Rotavirus Vaccine Sales, by Country K Units (2018-2023)
  • Table 173. MEA Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 174. MEA Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 175. MEA Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 176. Middle East Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 177. Middle East Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 178. Middle East Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 179. Africa Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 180. Africa Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 181. Africa Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 182. North America Human Rotavirus Vaccine Sales, by Country K Units (2018-2023)
  • Table 183. North America Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 184. North America Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 185. North America Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 186. United States Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 187. United States Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 188. United States Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 189. Canada Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 190. Canada Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 191. Canada Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 192. Mexico Human Rotavirus Vaccine Sales, by Type K Units (2018-2023)
  • Table 193. Mexico Human Rotavirus Vaccine Sales, by Application K Units (2018-2023)
  • Table 194. Mexico Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2018-2023)
  • Table 195. Human Rotavirus Vaccine: by Type(USD/Units)
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Human Rotavirus Vaccine: by Type(USD Million)
  • Table 206. Human Rotavirus Vaccine Rotarix , by Region USD Million (2025-2030)
  • Table 207. Human Rotavirus Vaccine Rotavac , by Region USD Million (2025-2030)
  • Table 208. Human Rotavirus Vaccine Rotavin-M1 , by Region USD Million (2025-2030)
  • Table 209. Human Rotavirus Vaccine Lanzhou Lamb , by Region USD Million (2025-2030)
  • Table 210. Human Rotavirus Vaccine Others , by Region USD Million (2025-2030)
  • Table 211. Human Rotavirus Vaccine: by Application(USD Million)
  • Table 212. Human Rotavirus Vaccine Hospitals , by Region USD Million (2025-2030)
  • Table 213. Human Rotavirus Vaccine Clinics , by Region USD Million (2025-2030)
  • Table 214. Human Rotavirus Vaccine Academic and Research , by Region USD Million (2025-2030)
  • Table 215. Human Rotavirus Vaccine Others , by Region USD Million (2025-2030)
  • Table 216. Human Rotavirus Vaccine: by Distribution Channel(USD Million)
  • Table 217. Human Rotavirus Vaccine Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 218. Human Rotavirus Vaccine Drug Stores , by Region USD Million (2025-2030)
  • Table 219. South America Human Rotavirus Vaccine, by Country USD Million (2025-2030)
  • Table 220. South America Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 221. South America Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 222. South America Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 223. Brazil Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 224. Brazil Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 225. Brazil Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 226. Argentina Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 227. Argentina Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 228. Argentina Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 229. Rest of South America Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 230. Rest of South America Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 231. Rest of South America Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 232. Asia Pacific Human Rotavirus Vaccine, by Country USD Million (2025-2030)
  • Table 233. Asia Pacific Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 234. Asia Pacific Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 235. Asia Pacific Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 236. China Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 237. China Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 238. China Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 239. Japan Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 240. Japan Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 241. Japan Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 242. India Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 243. India Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 244. India Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 245. South Korea Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 246. South Korea Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 247. South Korea Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 248. Taiwan Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 249. Taiwan Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 250. Taiwan Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 251. Australia Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 252. Australia Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 253. Australia Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 255. Rest of Asia-Pacific Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 256. Rest of Asia-Pacific Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 257. Europe Human Rotavirus Vaccine, by Country USD Million (2025-2030)
  • Table 258. Europe Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 259. Europe Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 260. Europe Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 261. Germany Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 262. Germany Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 263. Germany Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 264. France Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 265. France Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 266. France Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 267. Italy Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 268. Italy Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 269. Italy Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 270. United Kingdom Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 271. United Kingdom Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 272. United Kingdom Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 273. Netherlands Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 274. Netherlands Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 275. Netherlands Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 276. Rest of Europe Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 277. Rest of Europe Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 278. Rest of Europe Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 279. MEA Human Rotavirus Vaccine, by Country USD Million (2025-2030)
  • Table 280. MEA Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 281. MEA Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 282. MEA Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 283. Middle East Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 284. Middle East Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 285. Middle East Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 286. Africa Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 287. Africa Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 288. Africa Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 289. North America Human Rotavirus Vaccine, by Country USD Million (2025-2030)
  • Table 290. North America Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 291. North America Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 292. North America Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 293. United States Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 294. United States Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 295. United States Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 296. Canada Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 297. Canada Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 298. Canada Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 299. Mexico Human Rotavirus Vaccine, by Type USD Million (2025-2030)
  • Table 300. Mexico Human Rotavirus Vaccine, by Application USD Million (2025-2030)
  • Table 301. Mexico Human Rotavirus Vaccine, by Distribution Channel USD Million (2025-2030)
  • Table 302. Human Rotavirus Vaccine Sales: by Type(K Units)
  • Table 303. Human Rotavirus Vaccine Sales Rotarix , by Region K Units (2025-2030)
  • Table 304. Human Rotavirus Vaccine Sales Rotavac , by Region K Units (2025-2030)
  • Table 305. Human Rotavirus Vaccine Sales Rotavin-M1 , by Region K Units (2025-2030)
  • Table 306. Human Rotavirus Vaccine Sales Lanzhou Lamb , by Region K Units (2025-2030)
  • Table 307. Human Rotavirus Vaccine Sales Others , by Region K Units (2025-2030)
  • Table 308. Human Rotavirus Vaccine Sales: by Application(K Units)
  • Table 309. Human Rotavirus Vaccine Sales Hospitals , by Region K Units (2025-2030)
  • Table 310. Human Rotavirus Vaccine Sales Clinics , by Region K Units (2025-2030)
  • Table 311. Human Rotavirus Vaccine Sales Academic and Research , by Region K Units (2025-2030)
  • Table 312. Human Rotavirus Vaccine Sales Others , by Region K Units (2025-2030)
  • Table 313. Human Rotavirus Vaccine Sales: by Distribution Channel(K Units)
  • Table 314. Human Rotavirus Vaccine Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 315. Human Rotavirus Vaccine Sales Drug Stores , by Region K Units (2025-2030)
  • Table 316. South America Human Rotavirus Vaccine Sales, by Country K Units (2025-2030)
  • Table 317. South America Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 318. South America Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 319. South America Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 320. Brazil Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 321. Brazil Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 322. Brazil Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 323. Argentina Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 324. Argentina Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 325. Argentina Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 326. Rest of South America Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 327. Rest of South America Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 328. Rest of South America Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 329. Asia Pacific Human Rotavirus Vaccine Sales, by Country K Units (2025-2030)
  • Table 330. Asia Pacific Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 331. Asia Pacific Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 332. Asia Pacific Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 333. China Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 334. China Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 335. China Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 336. Japan Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 337. Japan Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 338. Japan Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 339. India Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 340. India Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 341. India Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 342. South Korea Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 343. South Korea Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 344. South Korea Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 345. Taiwan Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 346. Taiwan Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 347. Taiwan Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 348. Australia Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 349. Australia Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 350. Australia Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 351. Rest of Asia-Pacific Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 352. Rest of Asia-Pacific Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 353. Rest of Asia-Pacific Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 354. Europe Human Rotavirus Vaccine Sales, by Country K Units (2025-2030)
  • Table 355. Europe Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 356. Europe Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 357. Europe Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 358. Germany Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 359. Germany Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 360. Germany Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 361. France Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 362. France Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 363. France Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 364. Italy Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 365. Italy Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 366. Italy Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 367. United Kingdom Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 368. United Kingdom Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 369. United Kingdom Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 370. Netherlands Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 371. Netherlands Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 372. Netherlands Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 373. Rest of Europe Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 374. Rest of Europe Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 375. Rest of Europe Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 376. MEA Human Rotavirus Vaccine Sales, by Country K Units (2025-2030)
  • Table 377. MEA Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 378. MEA Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 379. MEA Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 380. Middle East Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 381. Middle East Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 382. Middle East Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 383. Africa Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 384. Africa Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 385. Africa Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 386. North America Human Rotavirus Vaccine Sales, by Country K Units (2025-2030)
  • Table 387. North America Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 388. North America Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 389. North America Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 390. United States Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 391. United States Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 392. United States Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 393. Canada Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 394. Canada Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 395. Canada Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 396. Mexico Human Rotavirus Vaccine Sales, by Type K Units (2025-2030)
  • Table 397. Mexico Human Rotavirus Vaccine Sales, by Application K Units (2025-2030)
  • Table 398. Mexico Human Rotavirus Vaccine Sales, by Distribution Channel K Units (2025-2030)
  • Table 399. Human Rotavirus Vaccine: by Type(USD/Units)
  • Table 400. Research Programs/Design for This Report
  • Table 401. Key Data Information from Secondary Sources
  • Table 402. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Rotavirus Vaccine: by Type USD Million (2018-2023)
  • Figure 5. Global Human Rotavirus Vaccine: by Application USD Million (2018-2023)
  • Figure 6. Global Human Rotavirus Vaccine: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Human Rotavirus Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Human Rotavirus Vaccine Share (%), by Country
  • Figure 9. Europe Human Rotavirus Vaccine Share (%), by Country
  • Figure 10. MEA Human Rotavirus Vaccine Share (%), by Country
  • Figure 11. North America Human Rotavirus Vaccine Share (%), by Country
  • Figure 12. Global Human Rotavirus Vaccine: by Type K Units (2018-2023)
  • Figure 13. Global Human Rotavirus Vaccine: by Application K Units (2018-2023)
  • Figure 14. Global Human Rotavirus Vaccine: by Distribution Channel K Units (2018-2023)
  • Figure 15. South America Human Rotavirus Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Human Rotavirus Vaccine Share (%), by Country
  • Figure 17. Europe Human Rotavirus Vaccine Share (%), by Country
  • Figure 18. MEA Human Rotavirus Vaccine Share (%), by Country
  • Figure 19. North America Human Rotavirus Vaccine Share (%), by Country
  • Figure 20. Global Human Rotavirus Vaccine: by Type USD/Units (2018-2023)
  • Figure 21. Global Human Rotavirus Vaccine share by Players 2023 (%)
  • Figure 22. Global Human Rotavirus Vaccine share by Players (Top 3) 2023(%)
  • Figure 23. Global Human Rotavirus Vaccine share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Bharat Biotech International Limited (India) Revenue, Net Income and Gross profit
  • Figure 28. Bharat Biotech International Limited (India) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 33. Lanzhou Institute of Biologicals Products Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 34. Lanzhou Institute of Biologicals Products Co., Ltd (China) Revenue: by Geography 2023
  • Figure 35. BIOVIRx Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. BIOVIRx Inc (United States) Revenue: by Geography 2023
  • Figure 37. Serum Institute of India Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 38. Serum Institute of India Pvt. Ltd. (India) Revenue: by Geography 2023
  • Figure 39. Biological E (India) Revenue, Net Income and Gross profit
  • Figure 40. Biological E (India) Revenue: by Geography 2023
  • Figure 41. Bio Farma (Indonesia) Revenue, Net Income and Gross profit
  • Figure 42. Bio Farma (Indonesia) Revenue: by Geography 2023
  • Figure 43. Global Human Rotavirus Vaccine: by Type USD Million (2025-2030)
  • Figure 44. Global Human Rotavirus Vaccine: by Application USD Million (2025-2030)
  • Figure 45. Global Human Rotavirus Vaccine: by Distribution Channel USD Million (2025-2030)
  • Figure 46. South America Human Rotavirus Vaccine Share (%), by Country
  • Figure 47. Asia Pacific Human Rotavirus Vaccine Share (%), by Country
  • Figure 48. Europe Human Rotavirus Vaccine Share (%), by Country
  • Figure 49. MEA Human Rotavirus Vaccine Share (%), by Country
  • Figure 50. North America Human Rotavirus Vaccine Share (%), by Country
  • Figure 51. Global Human Rotavirus Vaccine: by Type K Units (2025-2030)
  • Figure 52. Global Human Rotavirus Vaccine: by Application K Units (2025-2030)
  • Figure 53. Global Human Rotavirus Vaccine: by Distribution Channel K Units (2025-2030)
  • Figure 54. South America Human Rotavirus Vaccine Share (%), by Country
  • Figure 55. Asia Pacific Human Rotavirus Vaccine Share (%), by Country
  • Figure 56. Europe Human Rotavirus Vaccine Share (%), by Country
  • Figure 57. MEA Human Rotavirus Vaccine Share (%), by Country
  • Figure 58. North America Human Rotavirus Vaccine Share (%), by Country
  • Figure 59. Global Human Rotavirus Vaccine: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc. (United States)
  • Bharat Biotech International Limited (India)
  • GlaxoSmithKline plc. (United Kingdom)
  • Sanofi S.A. (France)
  • Lanzhou Institute of Biologicals Products Co., Ltd (China)
  • BIOVIRx Inc (United States)
  • Serum Institute of India Pvt. Ltd. (India)
  • Biological E (India)
  • Bio Farma (Indonesia)
Select User Access Type

Key Highlights of Report


Mar 2024 250 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Rotavirus Vaccine Quantitative research analysis
Global Human Rotavirus Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Human Rotavirus Vaccine market are Merck & Co., Inc. (United States), Bharat Biotech International Limited (India), GlaxoSmithKline plc. (United Kingdom), Sanofi S.A. (France), Lanzhou Institute of Biologicals Products Co., Ltd (China), BIOVIRx Inc (United States), Serum Institute of India Pvt. Ltd. (India), Biological E (India) and Bio Farma (Indonesia), to name a few.
"Increased Research and Development Investment " is seen as one of major influencing trends for Human Rotavirus Vaccine Market during projected period 2023-2030.
Rotarix segment in Global market to hold robust market share owing to "Increased Prevalence of Rotavirus Infection ".

Know More About Global Human Rotavirus Vaccine Report?

Have a Query? Click Here

Other Related Reports

Peptide Therapeutics Comprehensive Study by Type (Generic, Innovative), Application (Cancer Treatment, Metabolic, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, Re...
$ 3750
Collagen Peptides Comprehensive Study by Application (Food Products, Nutraceuticals, Sports nutrition, Dietary Supplements, Cosmetic Products, Others), Distribution Channel (Supermarket/Hypermarket, ...
$ 3750
Enzyme Replacement Therapy Comprehensive Study by Application (Gaucher Disease, Fabry Disease, MPS Disease, Gastrointestinal Disease, Others), Enzyme (Imiglucerase, Agalsidase Beta, Taliglucerase, V...
$ 3750
Diabetes Drugs Comprehensive Study by Type (Injectable Drugs, Oral Drugs), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational diabetes), Distribution Channel (Hospital Pharmacies, Retail Phar...
$ 3350
Weight Loss Drugs Comprehensive Study by Type (Liquid, Tablets), Application (Weight-reducing Aid, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Aspergillosis Drugs Comprehensive Study by Type (Allergic Bronchopulmonary Aspergillosis, Allergic Aspergillus Sinusitis, Invasive Aspergillosis, Cutaneous (skin) Aspergillosis, Chronic Pulmonary Asp...
$ 3750